Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408724 | 0.86 | DGAT1 (0.46) | DGAT1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL408898 | 0.85 | DGAT1 (0.48) | DGAT1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL408273 | 0.81 | DGAT1 (0.54) | DGAT1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL408173 | 0.80 | NPC1 (0.45) | DGAT1KDM4E | |
| SCHEMBL4293751 | 0.79 | ALDH1A1 (0.54) | DGAT1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29332031 | 0.78 | ALKBH1 (0.41) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL407419 | 0.78 | DGAT1 (0.54) | DGAT1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14319143 | 0.78 | DGAT1 (0.45) | DGAT1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL407232 | 0.77 | DGAT1 (0.40) | DGAT1SMN1; SMN2 | |
| SCHEMBL4486286 | 0.76 | SMN1; SMN2 (0.52) | DGAT1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885KDM4E 2452/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.